{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T06:46:22Z","timestamp":1795243582076,"version":"4.10.3"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T00:00:00Z","timestamp":1643846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T00:00:00Z","timestamp":1643846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"This study was funded by Astellas Pharma Inc.","award":["No grant number."],"award-info":[{"award-number":["No grant number."]}]},{"name":"This study was funded by Astellas Pharma Inc.","award":["No grant number."],"award-info":[{"award-number":["No grant number."]}]},{"name":"This study was funded by Astellas Pharma Inc.","award":["No grant number."],"award-info":[{"award-number":["No grant number."]}]},{"name":"This study was funded by Astellas Pharma Inc.","award":["No grant number."],"award-info":[{"award-number":["No grant number."]}]},{"name":"This study was funded by Astellas Pharma Inc.","award":["No grant number."],"award-info":[{"award-number":["No grant number."]}]},{"name":"This study was funded by Astellas Pharma Inc.","award":["No grant number."],"award-info":[{"award-number":["No grant number."]}]},{"name":"This study was funded by Astellas Pharma Inc.","award":["No grant number."],"award-info":[{"award-number":["No grant number."]}]},{"name":"This study was funded by Astellas Pharma Inc.","award":["No grant number."],"award-info":[{"award-number":["No grant number."]}]},{"name":"This study was funded by Astellas Pharma Inc.","award":["No grant number."],"award-info":[{"award-number":["No grant number."]}]},{"name":"This study was funded by Astellas Pharma Inc.","award":["No grant number."],"award-info":[{"award-number":["No grant number."]}]},{"name":"This study was funded by Astellas Pharma Inc.","award":["No grant number."],"award-info":[{"award-number":["No grant number."]}]},{"name":"This study was funded by Astellas Pharma Inc.","award":["No grant number."],"award-info":[{"award-number":["No grant number."]}]},{"name":"This study was funded by Astellas Pharma Inc.","award":["No grant number."],"award-info":[{"award-number":["No grant number."]}]},{"name":"This study was funded by Astellas Pharma Inc.","award":["No grant number."],"award-info":[{"award-number":["No grant number."]}]},{"name":"This study was funded by Astellas Pharma Inc.","award":["No grant number."],"award-info":[{"award-number":["No grant number."]}]},{"name":"This study was funded by Astellas Pharma Inc.","award":["No grant number."],"award-info":[{"award-number":["No grant number."]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Sodium\u2013glucose cotransporter 2 inhibitor (SGLT2i) treatment is a therapeutic approach for type 2 diabetes mellitus (T2DM). Some reports have shown that SGLT2i treatment improves insulin resistance; however, few studies have evaluated insulin resistance by the glucose clamp method. Hepatic insulin clearance (HIC) is a new pathophysiological mechanism of T2DM. The effect of SGLT2i treatment on hepatic insulin clearance and insulin resistance is not well known. We investigated the effect of SGLT2i treatment on insulin resistance, insulin secretion, incretin levels, body composition, and hepatic insulin clearance. We conducted a meal tolerance test (MTT) and a hyperinsulinemic-euglycemic clamp test in 9 T2DM patients. Ipragliflozin (50\u00a0mg\/day) was administered, and the MTT and clamp test were performed after 4\u00a0months. We calculated HIC as the postprandial C-peptide AUC-to-insulin AUC ratio. We also measured GLP-1, GIP, and glucagon levels during the MTT. Body weight and HbA1c were decreased, although not significantly, after 4\u00a0months of treatment. Postprandial glucose, fasting insulin and postprandial insulin were significantly decreased. Insulin resistance with the glucose clamp was not changed, but the HOMA-IR and insulin sensitivity indices were significantly improved. Incretin and glucagon levels were not changed. Hepatic insulin clearance was significantly increased, but whole-body insulin clearance was not changed. The FIB-4 index and fatty liver index were significantly reduced. The HOMA-beta and insulinogenic indices were not changed, but the C-peptide index was significantly increased. Although the number of patients was small, these results suggested that SGLT2i treatment improved liver function, decreased hepatic insulin resistance, and increased hepatic insulin clearance, despite the small weight reduction.<\/jats:p>","DOI":"10.1038\/s41598-022-05704-y","type":"journal-article","created":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T11:05:49Z","timestamp":1643886349000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["The sodium\u2013glucose cotransporter 2 inhibitor ipragliflozin improves liver function and insulin resistance in Japanese patients with type 2 diabetes"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3713-6617","authenticated-orcid":false,"given":"Tsuyoshi","family":"Okura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Fujioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risa","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonoko","family":"Kitao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Anno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhisa","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Shoji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Matsuzawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichiro","family":"Izawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Okura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etsuko","family":"Ueta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-ichi","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,3]]},"reference":[{"key":"5704_CR1","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/S0140-6736(13)62154-6","volume":"383","author":"SE Kahn","year":"2014","unstructured":"Kahn, S. E., Cooper, M. E. & Del Prato, S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet 383, 1068\u20131083 (2014).","journal-title":"Lancet"},{"key":"5704_CR2","doi-asserted-by":"publisher","first-page":"136","DOI":"10.4239\/wjd.v6.i1.136","volume":"6","author":"T Ohkura","year":"2015","unstructured":"Ohkura, T. Ipragliflozin: a novel sodium\u2013glucose cotransporter 2 inhibitor developed in Japan. World J. Diabetes. 6, 136\u2013144 (2015).","journal-title":"World J. Diabetes."},{"key":"5704_CR3","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1172\/JCI70704","volume":"124","author":"A Merovci","year":"2014","unstructured":"Merovci, A. et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J. Clin. Invest. 124, 509\u2013514 (2014).","journal-title":"J. Clin. Invest."},{"key":"5704_CR4","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1172\/JCI72227","volume":"124","author":"E Ferrannini","year":"2014","unstructured":"Ferrannini, E. et al. Metabolic response to sodium\u2013glucose cotransporter 2 inhibition in type 2 diabetic patients. J. Clin. Invest. 124, 499\u2013508 (2014).","journal-title":"J. Clin. Invest."},{"key":"5704_CR5","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1089\/dia.2013.0167","volume":"16","author":"S Mudaliar","year":"2014","unstructured":"Mudaliar, S. et al. Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin. Diabetes Technol. Ther. 16, 137\u2013144 (2014).","journal-title":"Diabetes Technol. Ther."},{"key":"5704_CR6","doi-asserted-by":"publisher","first-page":"3779","DOI":"10.2337\/dc12-1203","volume":"36","author":"O Pivovarova","year":"2013","unstructured":"Pivovarova, O. et al. Hepatic insulin clearance is closely related to metabolic syndrome components. Diabetes Care 36, 3779\u20133785 (2013).","journal-title":"Diabetes Care"},{"issue":"3","key":"5704_CR7","doi-asserted-by":"publisher","first-page":"258","DOI":"10.4158\/EP161323.OR","volume":"23","author":"E Ekholm","year":"2017","unstructured":"Ekholm, E. et al. Combined treatment with saxagliptin plus dapagliflozin reduces insulin levels by increased insulin clearance and improves beta-cell function. Endocr. Pract. 23(3), 258\u2013265 (2017).","journal-title":"Endocr. Pract."},{"key":"5704_CR8","doi-asserted-by":"publisher","first-page":"e001149","DOI":"10.1136\/bmjdrc-2019-001149","volume":"8","author":"T Okura","year":"2020","unstructured":"Okura, T. et al. Hepatic insulin clearance is increased in patients with high HbA1c type 2 diabetes: a preliminary report. BMJ Open Diabetes Res. Care. 8, e001149 (2020).","journal-title":"BMJ Open Diabetes Res. Care."},{"key":"5704_CR9","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1111\/dom.13584","volume":"21","author":"K Cusi","year":"2019","unstructured":"Cusi, K. et al. Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes. Diabetes Obes. Metab. 21, 812\u2013821 (2019).","journal-title":"Diabetes Obes. Metab."},{"key":"5704_CR10","doi-asserted-by":"publisher","first-page":"150","DOI":"10.2337\/dc14-2391","volume":"38","author":"WC Hsu","year":"2015","unstructured":"Hsu, W. C., Araneta, M. R., Kanaya, A. M., Chiang, J. L. & Fujimoto, W. BMI cut points to identify at-risk Asian Americans for type 2 diabetes screening. Diabetes Care 38, 150\u2013158 (2015).","journal-title":"Diabetes Care"},{"key":"5704_CR11","doi-asserted-by":"publisher","first-page":"e0201052","DOI":"10.1371\/journal.pone.0201052","volume":"13","author":"T Okura","year":"2018","unstructured":"Okura, T. et al. Body mass index \u226523 is a risk factor for insulin resistance and diabetes in Japanese people: A brief report. PLoS ONE 13, e0201052 (2018).","journal-title":"PLoS ONE"},{"key":"5704_CR12","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1002\/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S","volume":"15","author":"KG Alberti","year":"1998","unstructured":"Alberti, K. G. & Zimmet, P. Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med. 15, 539\u2013553 (1998).","journal-title":"Diabet. Med."},{"key":"5704_CR13","first-page":"361","volume":"49","author":"G Yoshino","year":"2006","unstructured":"Yoshino, G. et al. The test meal A: A pilot model for the international standard of test meal for an assessment of both postprandial hyperglycemia and hyperlipidemia. J. Jpn. Diabetes Soc. 49, 361\u2013371 (2006) ((In Japanese)).","journal-title":"J. Jpn. Diabetes Soc."},{"key":"5704_CR14","unstructured":"National Institutes of Diabetes and Digestive and Kidney Diseases, the HbA1c converter, [article online]. 1999. Available from: http:\/\/www.ngsp.org\/convert1.asp."},{"key":"5704_CR15","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/BF00280883","volume":"28","author":"DR Matthews","year":"1985","unstructured":"Matthews, D. R. et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412\u2013419 (1985).","journal-title":"Diabetologia"},{"key":"5704_CR16","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.2337\/diacare.22.9.1462","volume":"22","author":"M Matsuda","year":"1999","unstructured":"Matsuda, M. & DeFronzo, R. A. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22, 1462\u20131470 (1999).","journal-title":"Diabetes Care"},{"key":"5704_CR17","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.2337\/dc11-2006","volume":"35","author":"M Iwata","year":"2012","unstructured":"Iwata, M. et al. Genetic risk score constructed using 14 susceptibility alleles for type 2 diabetes is associated with the early onset of diabetes and may predict the future requirement of insulin injections among Japanese individuals. Diabetes Care 35, 1763\u20131770 (2012).","journal-title":"Diabetes Care"},{"key":"5704_CR18","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/dom.12817","volume":"19","author":"D Yabe","year":"2017","unstructured":"Yabe, D. et al. Effects of DPP-4 inhibitor linagliptin and GLP-1 receptor agonist liraglutide on physiological response to hypoglycaemia in Japanese subjects with type 2 diabetes: a randomized, open-label, 2-arm parallel comparative, exploratory trial. Diabetes Obes. Metab. 19, 442\u2013447 (2017).","journal-title":"Diabetes Obes. Metab."},{"key":"5704_CR19","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1475-2840-12-21","volume":"12","author":"T Ohkura","year":"2013","unstructured":"Ohkura, T. et al. 20\/(fasting C-peptide x fasting plasma glucose) is a simple and effective index of insulin resistance in patients with type 2 diabetes mellitus: a preliminary report. Cardiovasc. Diabetol. 12, 21 (2013).","journal-title":"Cardiovasc. Diabetol."},{"key":"5704_CR20","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1210\/jc.2004-1959","volume":"90","author":"Y Tamura","year":"2005","unstructured":"Tamura, Y. et al. Effects of diet and exercise on muscle and liver intracellular lipid contents and insulin sensitivity in type 2 diabetic patients. J. Clin. Endocrinol. Metab. 90, 3191\u20133196 (2005).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"5704_CR21","first-page":"214","volume":"237","author":"RA DeFronzo","year":"1979","unstructured":"DeFronzo, R. A., Tobin, J. D. & Andres, R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am. J. Physiol. 237, 214\u2013223 (1979).","journal-title":"Am. J. Physiol."},{"key":"5704_CR22","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","volume":"43","author":"RK Sterling","year":"2006","unstructured":"Sterling, R. K. et al. APRICOT Clinical Investigators Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology 43, 1317\u20131325 (2006).","journal-title":"Hepatology"},{"key":"5704_CR23","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-230X-6-33","volume":"6","author":"G Bedogni","year":"2006","unstructured":"Bedogni, G. et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 6, 33 (2006).","journal-title":"BMC Gastroenterol."},{"key":"5704_CR24","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda, Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 48, 452\u2013458 (2013).","journal-title":"Bone Marrow Transplant."},{"key":"5704_CR25","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1111\/dom.13211","volume":"20","author":"R Matsuba","year":"2018","unstructured":"Matsuba, R., Matsuba, I., Shimokawa, M., Nagai, Y. & Tanaka, Y. Tofogliflozin decreases body fat mass and improves peripheral insulin resistance. Diabetes Obes. Metab. 20, 1311\u20131315 (2018).","journal-title":"Diabetes Obes. Metab."},{"key":"5704_CR26","doi-asserted-by":"publisher","first-page":"931","DOI":"10.2337\/dc18-1569","volume":"42","author":"A Latva-Rasku","year":"2019","unstructured":"Latva-Rasku, A. et al. The SGLT2 inhibitor dapagliflozin reduces liver fat but does not affect tissue insulin sensitivity: a randomized, double-blind, placebo-controlled study with 8-week treatment in type 2 diabetes patients. Diabetes Care 42, 931\u2013937 (2019).","journal-title":"Diabetes Care"},{"key":"5704_CR27","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1111\/dom.13980","volume":"22","author":"Y Matsubayashi","year":"2020","unstructured":"Matsubayashi, Y. et al. Association of increased hepatic insulin clearance and change in serum triglycerides or beta-hydroxybutyrate concentration via the sodium\/glucose-cotransporter 2 inhibitor tofogliflozin. Diabetes Obes. Metab. 22, 947\u2013956 (2020).","journal-title":"Diabetes Obes. Metab."},{"key":"5704_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.molmet.2018.10.009","volume":"19","author":"T Suga","year":"2019","unstructured":"Suga, T. et al. SGLT1 in pancreatic \u03b1 cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels. Mol. Metab. 19, 1\u201312 (2019).","journal-title":"Mol. Metab."},{"key":"5704_CR29","doi-asserted-by":"publisher","first-page":"E15","DOI":"10.1152\/ajpendo.00645.2007","volume":"294","author":"R Muniyappa","year":"2008","unstructured":"Muniyappa, R., Lee, S., Chen, H. & Quon, M. J. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am. J. Physiol. Endocrinol. Metab. 294, E15-26 (2008).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"5704_CR30","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.3390\/biomedicines9091154","volume":"9","author":"M Sato","year":"2021","unstructured":"Sato, M. et al. Short-term SGLT2 inhibitor administration does not alter systemic insulin clearance in type 2 diabetes. Biomedicines. 9, 1154 (2021).","journal-title":"Biomedicines."},{"key":"5704_CR31","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJM198205203062002","volume":"306","author":"D Elahi","year":"1982","unstructured":"Elahi, D. et al. Feedback inhibition of insulin secretion by insulin: relation to the hyperinsulinemia of obesity. N Engl. J. Med. 306, 1196\u20131202 (1982).","journal-title":"N Engl. J. Med."},{"key":"5704_CR32","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.2337\/dc20-0750","volume":"43","author":"F Piccinini","year":"2020","unstructured":"Piccinini, F. & Bergman, R. N. The measurement of insulin clearance. Diabetes Care 43, 2296\u20132302 (2020).","journal-title":"Diabetes Care"},{"key":"5704_CR33","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.diabres.2008.09.010","volume":"82","author":"S Funakoshi","year":"2008","unstructured":"Funakoshi, S. et al. Analysis of factors influencing pancreatic beta-cell function in Japanese patients with type 2 diabetes: association with body mass index and duration of diabetic exposure. Diabetes Res. Clin. Pract. 82, 353\u2013358 (2008).","journal-title":"Diabetes Res. Clin. Pract."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-05704-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-05704-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-05704-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T22:22:43Z","timestamp":1669328563000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-05704-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,3]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["5704"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-05704-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,3]]},"assertion":[{"value":"29 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1896"}}